Citations

Showing 10 of 108152 citations.

Closure of Scalp and Forehead Defects Using External Tissue Expander
O’Reilly, Ashley G., Schmitt, William R., Roenigk, Randall K., Moore, Eric J. , Price, Daniel L.

Mayo Clinic

Archives of Facial Plastic Surgery | May 28, 2021 | Volume: 14 | Issue: 6 | Pages: 419-422

10.1001/archfaci.2012.662 Get It

Evaluation of the Midforehead Brow-lift Operation
Powell, Benjamin, Younes, Ahmed , Friedman, Oren A

Mayo Clinic

Archives of Facial Plastic Surgery | May 28, 2021 | Volume: 13 | Issue: 5 | Pages: 337-342

10.1001/archfaci.2011.64 Get It

Modified Back-to-Back Autogenous Conchal Cartilage Graft for Caudal Septal Reconstruction
Koch, Cody A., Friedman, Oren A

Mayo Clinic

Archives of Facial Plastic Surgery | May 28, 2021 | Volume: 13 | Issue: 1 | Pages: 20-25

10.1001/archfaci.2010.107 Get It

How I Approach Screening for Pancreatic Cancer
Fuente, Jaime de la , Kastrinos, Fay , Majumder, Shounak , Majumder, Shounak

Mayo Clinic

American Journal of Gastroenterology | May 28, 2021 | Volume: 116 | Issue: 8 | Pages: 1569-1571

10.14309/ajg.0000000000001305 | PMID 34047301 Get It

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
Shah, Eric D. , Lacy, Brian E. , Chey, William D. , Shah, Eric D , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | May 28, 2021 | Volume: 116 | Issue: 8 | Pages: 1601-1611

10.14309/ajg.0000000000001313 | PMID 34047303 Get It

INTRODUCTION: Tegaserod was the first US Food and Drug Administration–approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. METHODS: Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients with IBS-C were pooled. We analyzed 2 groups: all women (overall population) and women younger than 65 years without a history of cardiovascular ischemic events (indicated population). The primary end point was subjective global assessment of IBS-C symptom relief. Responders rated themselves as “considerably” or “completely” relieved ≥50% of the time or at least “somewhat relieved” 100% of the time over the last 4 weeks. RESULTS: The overall and indicated populations included 2,939 (tegaserod [n = 1,478]; placebo [n = 1,461]) and 2,752 (tegaserod [n = 1,386]; placebo [n = 1,366]) participants, respectively. The pooled odds ratios (95% confidence interval) for clinical response during the last 4 weeks in the overall and indicated populations with tegaserod were 1.37 (1.18, 1.59; P < 0.001) and 1.38 (1.18, 1.61; P < 0.001). In the overall and indicated populations, clinical response rates for tegaserod during the last 4 weeks were 43.3% and 44.1% versus 35.9% and 36.5% with placebo ( P < 0.001). Adverse events were similar between groups. No significant cardiovascular events related to tegaserod were observed in patients with ≤1 cardiac risk factor. DISCUSSION: Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration–indicated populations (women aged <65 years with no history of cardiovascular ischemic events).
GPCR‐mediated YAP/TAZ inactivation in fibroblasts via EPAC1/2, RAP2C, and MAP4K7
Choi, Kyoung Moo , Haak, Andrew J. , Espinosa, Ana M. Diaz , Cummins, Katherine A. , Link, Patrick A. , Aravamudhan, Aja, Tschumperlin, Daniel J. , Diaz Espinosa, Ana M , Tschumperlin, Daniel J , Link, Patrick A , Wood, David K.

Mayo Clinic

Journal of Cellular Physiology | May 28, 2021 | Volume: 236 | Issue: 11 | Pages: 7759-7774

10.1002/jcp.30459 | PMID 34046891 Get It

AbstractYes‐associated protein (YAP) and PDZ‐binding motif (TAZ) have emerged as important regulators of pathologic fibroblast activation in fibrotic diseases. Agonism of Gαs‐coupled G protein coupled receptors (GPCRs) provides an attractive approach to inhibit the nuclear localization and function of YAP and TAZ in fibroblasts that inhibits or reverses their pathological activation. Agonism of the dopamine D1 GPCR has proven effective in preclinical models of lung and liver fibrosis. However, the molecular mechanisms coupling GPCR agonism to YAP and TAZ inactivation in fibroblasts remain incompletely understood. Here, using human lung fibroblasts, we identify critical roles for the cAMP effectors EPAC1/2, the small GTPase RAP2c, and the serine/threonine kinase MAP4K7 as the essential elements in the downstream signaling cascade linking GPCR agonism to LATS1/2‐mediated YAP and TAZ phosphorylation and nuclear exclusion in fibroblasts. We further show that this EPAC/RAP2c/MAP4K7 signaling cascade is essential to the effects of dopamine D1 receptor agonism on reducing fibroblast proliferation, contraction, and extracellular matrix production. Targeted modulation of this cascade in fibroblasts may prove a useful strategy to regulate YAP and TAZ signaling and fibroblast activities central to tissue repair and fibrosis.
Pathology of breast cancer metastasis and a view of metastasis to the brain
Sakibuzzaman, Md , Mahmud, Shahriar , Afroze, Tanzina , Fathma, Sawsan, Zakia, Ummul Barakat, Afroz, Sabrina, Zafar, Farzina, Hossain, Maksuda , Barua, Amit , Akter, Sabiha, Chowdhury, Hasanul Islam, Ahsan, Eram, Eshan, Shayet Hossain, Fariza, Tasnuva Tarannum, Akter, Sabiha

Mayo Clinic

International Journal of Neuroscience | May 28, 2021 | Volume: 133 | Issue: 5 | Pages: 544-554

10.1080/00207454.2021.1935929 | PMID 34044732 Get It

Associations of Vasopressor Requirements With Echocardiographic Parameters After Out-of-Hospital Cardiac Arrest
Burstein, Barry , Anavekar, Nandan S., Jentzer, Jacob C. , Burstein, Barry J, Jentzer, Jacob C , Tabi, Meir , Kashani, Kianoush

Mayo Clinic

Journal of Intensive Care Medicine | May 28, 2021 | Volume: 37 | Issue: 4 | Pages: 518-527

10.1177/0885066621998936 | PMID 34044666 Get It

Background: Post-arrest hypotension is common after out of hospital cardiac arrest (OHCA) and many patients resuscitated after OHCA will require vasopressors. We sought to determine the associations between echocardiographic parameters and vasopressor requirements in OHCA patients. Methods: We retrospectively analyzed adult patients with OHCA treated with targeted temperature management between December 2005 and September 2016 who underwent a transthoracic echocardiogram (TTE). Categorical variables were compared using 2-tailed Fisher’s exact and Pearson’s correlation coefficients and variance (r 2 ) values were used to assess relationships between continuous variables. Results: Among 217 included patients, the mean age was 62 ± 12 years, including 74% males. The arrest was witnessed in 90%, the initial rhythm was shockable in 88%, and 58% received bystander CPR. At the time of TTE, 41% of patients were receiving vasopressors; this group of patients was older, had greater severity of illness, higher inpatient mortality and left ventricular ejection fraction (LVEF) was modestly lower (36.8 ± 17.1% vs. 41.4 ± 16.4%, P = 0.04). Stroke volume, cardiac power output and left ventricular stroke work index correlated with number of vasopressors (Pearson r −0.24 to −0.34, all P < 0.002), but the correlation with LVEF was weak (Pearson r −0.13, P = 0.06). Conclusions: In patients after OHCA, left ventricular systolic dysfunction was associated with the need for vasopressors, and Doppler TTE hemodynamic parameters had higher correlation coefficients compared with vasopressor requirements than LVEF. This emphasizes the complex nature of shock after OHCA, including pathophysiologic processes not captured by TTE assessment alone.
Personal and Professional Factors Associated With Work-Life Integration Among US Physicians
Tawfik, Daniel , Shanafelt, Tait D. , Sinsky, Christine A. , Davis, Alexis S. , Su, Felice , Adair, Kathryn C. , Trockel, Mickey , Profit, Jochen , Dyrbye, Liselotte N. , Shanafelt, Tait D , West, Colin P. , Sexton, John Bryan

Mayo Clinic

JAMA Network Open | May 28, 2021 | Volume: 4 | Issue: 5 | Pages: e2111575

10.1001/jamanetworkopen.2021.11575 | PMID 34042994 Get It

The Impact of the COVID-19 Pandemic on Self-Reported Outcomes in Patients With Adrenal Insufficiency
Li, Dingfeng , Suresh, Malavika, Abbondanza, Tiffany, Vaidya, Anand , Bancos, Irina , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 28, 2021 | Volume: 106 | Issue: 7 | Pages: e2469-e2479

10.1210/clinem/dgab334 | PMID 34042985 Get It

AbstractContextThe COVID-19 pandemic has impacted healthcare environment.ObjectiveTo determine the impact of the pandemic on self-reported outcomes in patients with adrenal insufficiency (AI).Design and settingProspective longitudinal survey study at 2 tertiary centers.ParticipantsPatients with AI.InterventionPatient-centered questionnaire.Main outcome measuresDepression Anxiety Stress Scales-21, Short Form-36, and AI self-management.ResultsOf 342 patients, 157 (46%) had primary AI, 109 (32%) had secondary AI, and 76 (22%) had glucocorticoid-induced AI. When compared to prepandemic, daily glucocorticoid dose and number of adrenal crises did not change. However, patients reported a higher financial impact from AI (34% vs 23%, P = 0.006) and difficulty accessing medical care (31% vs 7%, P &lt; 0.0001) during the pandemic. A third of patients reported difficulty managing AI during the pandemic. After adjusting for duration and subtypes of AI, younger patients [odds ratio (OR) 2.3, CI 95% 1.3-4.1], women (OR 3.7, CI 95% 1.9-7.1), poor healthcare access(OR 4.2, CI 95% 2.3-7.7), lack of good insurance support (OR 2.8, CI 95% 1.3-5.9), and those with a higher financial impact (OR 2.3, CI 95% 1.3-4.3) reported greater difficulties managing AI. Patients were more likely to report a higher anxiety score (≥8) if they found managing AI challenging during the pandemic (OR 3.0, CI 95% 1.3-6.9), and had lower Physical Component Summary (OR 4.9, CI 95% 2.2-11.0) and Mental Component Summary (OR 4.1, CI 95% 1.8-9.5) scores prior to the pandemic.ConclusionsA third of patients with AI reported difficulties with management of AI during the pandemic, particularly in younger patients, women, and those with poor healthcare access.